TheraCryf plc (AIM: TCF), the clinical stage drug development company focussing on oncology and neuropsychiatry, announces that Dr Huw Jones, Chief Executive Officer, and Dr Alastair Smith, Non-executive Chair, hosted an investor webinar on Wednesday, 2 April 2025 at 6.00 pm (BST).

The webinar is open to all existing and potential investors and will focus on the Company’s plans to drive its Ox-1 addiction and SFX-01 glioblastoma programmes, following the fundraise which completed earlier this month. These funds will enable the Company to take the Orexin-1 antagonist to the key inflection point of clinical trial readiness, allowing it to unlock potential commercial opportunities.

We are delighted to announce that the webinar was chaired by experienced news and corporate events presenter Katie Pilbeam (www.katiepilbeam.com) and hosted by the Company’s broker, Turner Pope Investments.